Summit Street Capital Management, LLC Gilead Sciences, Inc. Transaction History

Summit Street Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $1.69 Million - $1.84 Million	-22,800 Reduced 47.63%	25,064 $1.88 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $559,661 - $638,372	-7,363 Reduced 13.33%	47,864 $3.69 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $812,669 - $887,957	12,804 Added 30.18%	55,227 $3.8 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $2.55 Million - $2.9 Million	42,423 New	42,423 $2.74 Million
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $1.69 Million - $1.92 Million	-29,792 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $1.87 Million - $2.39 Million	29,792 New	29,792 $2.23 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $2.94 Million - $3.83 Million	-48,492 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $3.5 Million - $4.14 Million	48,492	48,492 $3.93 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Summit Street Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Summit Street Capital Management, LLC with notifications on news.